{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:45:17Z","timestamp":1787067917226,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.coi.2025.102703","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T01:39:14Z","timestamp":1764898754000},"page":"102703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Interferons in Sjogren\u2019s disease: current status and future prospects"],"prefix":"10.1016","volume":"98","author":[{"given":"Sylvia","family":"Raftopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios-Dimitrios","family":"Bakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio P","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102703_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.autrev.2016.03.004","article-title":"Primary Sj\u04e7gren\u2019s syndrome: clinical phenotypes, outcome and the development of biomarkers","volume":"15","author":"Goules","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102703_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003291","article-title":"Comparison between primary Sj\u00f6gren\u2019s disease patients with high or low level of dryness","volume":"9","author":"Kachaner","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102703_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sj\u00f6gren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.coi.2025.102703_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110716","article-title":"Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome","volume":"123","author":"Sun","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102703_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/JIR.S414320","article-title":"Nomogram based on inflammatory factor to predict therapeutic response of thrombocytopenia in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Gan","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.coi.2025.102703_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2478\/rir-2023-0012","article-title":"UK primary Sj\u00f6gren\u2019s Syndrome Registry. Depression in Sj\u00f6gren\u2019s syndrome mediates the relationship between pain, fatigue, sleepiness, and overall quality of life","volume":"4","author":"Costa","year":"2023","journal-title":"Rheumatol Immunol Res"},{"key":"10.1016\/j.coi.2025.102703_bib7","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib8","first-page":"164","article-title":"Circulating interferon in human autoimmune diseases","volume":"41","author":"Hooks","year":"1981","journal-title":"Tex Rep Biol Med"},{"key":"10.1016\/j.coi.2025.102703_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0079-6603(08)60026-4","article-title":"The interferon genes","volume":"33","author":"Weissmann","year":"1986","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"10.1016\/j.coi.2025.102703_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2025.102703_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.coi.2025.102703_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102413","article-title":"Structure-function of type I and III interferons","volume":"86","author":"de Weerd","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102703_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.biochi.2007.01.008","article-title":"IL-28 and IL-29: newcomers to the interferon family","volume":"89","author":"Uz\u00e9","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.coi.2025.102703_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coviro.2015.02.003","article-title":"The unique regulation and functions of type III interferons in antiviral immunity","volume":"12","author":"Odendall","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coi.2025.102703_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000369459","article-title":"Role of interferon-\u03bb in allergic asthma","volume":"7","author":"Koch","year":"2015","journal-title":"J Innate Immun"},{"key":"10.1016\/j.coi.2025.102703_bib17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1490","article-title":"Recent developments in the transcriptional regulation of cytolytic effector cells","volume":"4","author":"Glimcher","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102703_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coi.2025.102703_bib20","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102703_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jir.2010.0063","article-title":"Mechanisms of type III interferon expression","volume":"30","author":"Iversen","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.coi.2025.102703_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2025.102703_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-\u03bb: immune functions at barrier surfaces and beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102703_bib24","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102703_bib25","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.1301705","article-title":"IFN-\u03bb exerts opposing effects on T cell responses depending on the chronicity of the virus infection","volume":"192","author":"Misumi","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib26","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","article-title":"Innate immunity and interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Bodewes","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib27","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/rheumatology\/keab688","article-title":"Serum interferon-\u03b12 measured by single-molecule array associates with systemic disease manifestations in Sj\u00f6gren\u2019s syndrome","volume":"61","author":"Huijser","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib28","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren\u2019s syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102703_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002694","article-title":"Phosphorylated signal transducer and activator of transcription proteins 1 in salivary glandular tissue: an important histological marker for diagnosis of primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Zheng","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102703_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109739","article-title":"Non-invasive diagnosis of primary Sj\u00f6gren\u2019s syndrome using ultrasonography and transcriptome biomarkers","volume":"255","author":"Xu","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102704","article-title":"Interferon (IFN)-stimulated gene 15: a novel biomarker for lymphoma development in Sj\u00f6gren\u2019s syndrome","volume":"123","author":"Cinoku","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102703_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3899\/jrheum.2023-1068","article-title":"Increased interferon signaling in vaginal tissue of patients with primary Sj\u00f6gren syndrome","volume":"51","author":"Visser","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/ard.2009.118158","article-title":"Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren\u2019s syndrome","volume":"69","author":"Vogelsang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102703_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02096","article-title":"Plasmacytoid DCs from patients with Sj\u00f6gren\u2019s syndrome are transcriptionally primed for enhanced pro-inflammatory cytokine production","volume":"10","author":"Hillen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib37","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Long interspersed nuclear element-1 retroelements are expressed in patients with systemic autoimmune disease and induce type I interferon","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_sbref38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/art.42844","article-title":"Amplified type I interferon response in Sj\u00f6gren\u2019s disease via ectopic toll-like receptor 7 expression in salivary gland epithelial cells induced by lysosome-associated membrane protein 3","volume":"76","author":"Nakamura","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_sbref39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard-2024-226224","article-title":"m6A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sj\u00f6gren\u2019s disease","volume":"84","author":"Truffinet","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102703_sbref40","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard-2023-225069","article-title":"CD8+ tissue-resident memory T cells are expanded in primary Sj\u00f6gren\u2019s disease and can be therapeutically targeted by CD103 blockade","volume":"83","author":"Mauro","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102703_bib41","article-title":"Ocular surface involvements in the development of Sj\u00f6gren\u2019s Syndrome-associated dry eye in the IL14\u03b1 transgenic mouse","volume":"66","author":"Zhang","year":"2025","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.coi.2025.102703_bib42","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMoa2312665","article-title":"The role of interferon-\u03b3 in autoimmune polyendocrine syndrome type 1","volume":"390","author":"Oikonomou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102703_bib43","first-page":"31","article-title":"Increased expression of interferon-\u03bb in minor salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome and its synergic effect with interferon-\u03b1 on salivary gland epithelial cells","volume":"36","author":"Ha","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12865","article-title":"Expression of type III interferons (IFN\u03bbs) and their receptor in Sj\u00f6gren\u2019s syndrome","volume":"186","author":"Apostolou","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib45","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1038\/s44318-025-00539-5","article-title":"Basal IFN-\u03bb2\/3 expression mediates tight junction formation in human epithelial cells","volume":"44","author":"Keser","year":"2025","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2025.102703_sbref46","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1093\/rheumatology\/kead096","article-title":"Identification of new candidate drugs for primary Sj\u00f6gren\u2019s syndrome using a drug repurposing transcriptomic approach","volume":"62","author":"Felten","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard-2022-222728","article-title":"Deciphering the role of cDC2s in Sj\u00f6gren\u2019s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity","volume":"82","author":"Lopes","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102703_bib48","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.43207","article-title":"Deep immunophenotyping and clustering identifies biomarkers predictive of lymphoma in primary Sj\u00f6gren disease","volume":"77","author":"Marques","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-63935-9","article-title":"Comparative single-cell and spatial profiling of anti-SSA-positive and anti-centromere-positive Sj\u00f6gren\u2019s disease reveals common and distinct immune activation and fibroblast-mediated inflammation","volume":"16","author":"Inamo","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102703_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001184","article-title":"Autoantigen TRIM21\/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sj\u00f6gren\u2019s syndrome is associated with B cell hyperactivity and type I interferon activity","volume":"6","author":"Hillen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102703_sbref51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/art.42789","article-title":"Association of combined anti-Ro52\/TRIM21 and anti-Ro60\/SSA antibodies with increased Sj\u00f6gren disease severity through interferon pathway activation","volume":"76","author":"Bettacchioli","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_sbref52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.43096","article-title":"Distinct pathophysiologic pathways support stratification of Sj\u00f6gren\u2019s disease based on symptoms, clinical, and routine biological data","volume":"77","author":"Nguyen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840751","article-title":"Trained immunity in primary Sj\u00f6gren\u2019s syndrome: linking type I interferons to a pro-atherogenic phenotype","volume":"13","author":"Huijser","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0613-6","article-title":"Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren\u2019s syndrome: prevalence, clinical and laboratory associations","volume":"17","author":"Gravani","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2025.102703_sbref55","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ard.2025.07.021","article-title":"Transcriptomic profiling of Sj\u00f6gren\u2019s disease salivary glands identifies signatures associated with both follicular and extrafollicular responses linked to rheumatoid factor and anti-La\/SSB seropositivity","volume":"84","author":"Pontarini","year":"2025","journal-title":"Ann Rheum\u00a0Dis"},{"key":"10.1016\/j.coi.2025.102703_bib56","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1093\/rheumatology\/keaf158","article-title":"Kynurenines and neopterin are interferon-gamma-inducible biomarkers for Sj\u00f6gren\u2019s disease","volume":"64","author":"Valim","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib57","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren\u2019s syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coi.2025.102703_bib58","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_sbref60","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41423-025-01346-y","article-title":"The STING\/type I interferon axis drives the interplay between marginal zone B cells and T follicular helper cells in Sj\u00f6gren\u2019s disease","volume":"22","author":"Chen","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102703_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005351","article-title":"Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases","volume":"11","author":"Bj\u00f6rk","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102703_bib62","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_bib63","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1093\/rheumatology\/keaf173","article-title":"Evaluating the therapeutic potential of tofacitinib in Sj\u00f6gren\u2019s disease: a comprehensive clinical and immunological assessment","volume":"64","author":"Liu","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102703_sbref64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/ard-2023-224842","article-title":"Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sj\u00f6gren\u2019s disease","volume":"83","author":"Gupta","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102703_bib65","article-title":"A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren\u2019s syndrome patients","volume":"24","author":"Bai","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.coi.2025.102703_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado4856","article-title":"IFN-\u03b3-producing TH1 cells and dysfunctional regulatory T cells contribute to the pathogenesis of Sj\u00f6gren\u2019s disease","volume":"16","author":"Wang","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102703_bib67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","article-title":"Genetics and epigenetics of primary Sj\u00f6gren syndrome: implications for future therapies","volume":"19","author":"Thorlacius","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102703_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102703_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-002979","article-title":"Leflunomide\/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sj\u00f6gren\u2019s syndrome that show potential to predict and monitor clinical response","volume":"9","author":"Hamkour","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102703_sbref70","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ard.2025.04.020","article-title":"Development of salivary gland organoids derived from patient biopsies: a functional model of Sj\u00f6gren\u2019s disease","volume":"84","author":"Meudec","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:01:18Z","timestamp":1780635678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":70,"alternative-id":["S0952791525001797"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102703","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferons in Sjogren\u2019s disease: current status and future prospects","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102703"}}